预约演示
更新于：2025-08-31
Scopolamine Butylbromide
丁溴东莨菪碱
更新于：2025-08-31
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1955-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H30BrNO4 |
InChIKeyHOZOZZFCZRXYEK-GSWUYBTGSA-M |
CAS号149-64-4 |
关联
97
项与 丁溴东莨菪碱 相关的临床试验NCT06398054
Comparison of the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy: a Randomized, Phase iv, Double-blind Trial
PACTR202502489216837
Effect of hyoscine -n-butylbromide on the duration of active phase of labour in term pregnancies: a randomized-controlled clinical trial.
PACTR202407560838827
Cervical ripening /Labour induction in postdate nulliparas; Comparative study of vaginal misoprostol versus vaginal misoprostol with rectal hyoscine-butylbromide
100 项与 丁溴东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 丁溴东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 丁溴东莨菪碱 相关的专利（医药）
登录后查看更多信息
929
项与 丁溴东莨菪碱 相关的文献（医药）2025-09-01Integrative Medicine Research
Efficacy of herbal medicine (Thatbunjob) in the treatment of foodborne illness: A placebo-controlled, randomized trial
Article
作者: Bhanthumkomol, Patommatat ; Eiamsitrakoon, Thanee ; Sakpakdeejaroen, Intouch ; Jaicharoensub, Jaiboonya ; Panthong, Sumalee
Background:
Foodborne illness (FI) causes 600 million cases and 420,000 deaths annually. Current treatments focus on rehydration and antispasmodic medications for managing dehydration and abdominal pain (AP). However, alternative therapies, especially those derived from natural ingredients, are needed. This study investigates the potential efficacy of herbal medicine,Thatbunjob as a complementary therapy for FI-related AP.
Methods:
A double-blind, randomized, placebo-controlled clinical trial assessed the efficacy of Thatbunjob in relieving AP in FI patients. A total of 114 patients, aged 18-60, with AP and diarrhea (≥3 episodes in 24 h), received either two 500 mg capsules of Thatbunjob or a placebo three times daily for three days. Both groups also received standard oral rehydration therapy. Primary outcomes included AP intensity using a visual analog scale (VAS) at 24 h, while secondary outcomes included pain at 48 and 72 h, responder rates, hyoscine butyl bromide usage, stool frequency, and adverse events.
Results:
The Thatbunjob group showed significantly greater reduction in AP compared to the placebo. VAS scores decreased from 5.69 to 2.95 at 24 h (P < 0.001), and pain relief persisted at 48 (1.43 vs. 3.05, P < 0.001) and 72 h (0.32 vs. 1.86, P < 0.001). Thatbunjob also reduced the need for hyoscine tablets and decreased stool frequency compared to placebo.
Conclusion:
This study demonstrates that Thatbunjob, when combined with standard rehydration therapy, effectively alleviates AP and reduces stool frequency in FI patients.
Trial registration:
Thai Clinical Trials Registry, TCTR20220823001.
2025-06-01British Journal of Pharmacology
Oral hyoscine butylbromide exerts spasmolytic effects in both gastrointestinal and urogenital tissues in rats
Article
作者: Lange, Robert ; Appelqvist, Terence ; Corsetti, Maura ; Jimenez, Marcel ; Traserra, Sara
Background and Purpose:
Hyoscine butylbromide (HBB) has a low oral (PO) bioavailability. Further, limited data on its activity on non‐gastrointestinal (GI) smooth muscle spasms after oral dosing are available, causing its effects beyond the GI tract to be questioned. This pharmacokinetic/pharmacodynamic (PK/PD) study, conducted using female rats, aimed to cover this gap.
Experimental Approach:
PK study: HBB and atropine (as a comparator agent) were administered PO and IV to rats, and concentrations in plasma and tissues (colon, uterus and urinary bladder; CUB) were measured. PD study 1: concentration–response curves of HBB and atropine (10−9–10−4 M) were obtained for carbachol‐induced (10−5 M) pre‐contracted tissues; PD study 2: CUB were pre‐incubated with HBB and atropine at maximum concentrations (Cmax) from PK studies and carbachol concentration–response curves (10−9–10−4 M) were obtained; PD study 3: HBB and atropine were administered PO and IV to rats as for PK study, CUB tissues were collected at 0.5 h (IV) and 4 h (PO), and carbachol concentration–response curves (10−9–10−4 M) obtained.
Key Results:
PO HBB showed higher Cmax in CUB tissues than in plasma. HBB and atropine reduced, concentration‐dependently, carbachol‐induced contractions in CUB tissues. PO HBB showed highest spasmolytic activity in colon (40%), followed by uterus (30%) and urinary bladder (10%).
Conclusion and Implications:
This is the first comparison of PO and IV HBB and atropine in GI and non‐GI tissues. Despite low bioavailability, PO HBB accumulated and exerted spasmolytic effects in tissues beyond the GI tract.
2025-05-01MAGNETIC RESONANCE IMAGING
Use of deep learning-accelerated T2 TSE for prostate MRI: Comparison with and without hyoscine butylbromide admission
Article
作者: Valentin, B ; Drewes, L ; Wittsack, H J ; Radtke, J P ; Antoch, G ; Albers, P ; Boschheidgen, M ; Ullrich, T ; Trappe, S ; Al-Monajjed, R ; Schimmöller, L
OBJECTIVE:
To investigate the use of deep learning (DL) T2-weighted turbo spin echo (TSE) imaging sequence with deep learning acceleration (T2DL) in prostate MRI regarding the necessity of hyoscine butylbromide (HBB) administration for high image quality.
METHODS:
One hundred twenty consecutive patients divided into four groups (30 for each group) were included in this study. All patients received a T2DL (version 2022/23) and a conventional T2 TSE (cT2) sequence on an implemented 3 T scanner and software system. Group A received cT2 with HBB compared to T2DL without HBB with a field of view (FOV) of 130 mm and group B with a FOV of 160 mm. Group C received both sequences with a FOV of 160 mm plus HBB and group D without HBB. Two radiologists independently evaluated all imaging datasets in a blinded reading regarding motion, sharpness, noise, and diagnostic confidence. Furthermore, we analyzed quantitative parameters by calculating edge rise distance (ERD), signal-to-noise-ratio (SNR), and contrast-to-noise-ratio (CNR). Friedman test was used for group comparisons.
RESULTS:
Baseline characteristics showed no significant differences between groups A-D. After HBB cT2 showed less motion artifacts, more sharpness, and a higher diagnostic confidence than T2DL, though DL sequences had significantly lower noise (p < 0.01). Quantitative analysis revealed higher SNR and CNR for T2DL sequences (p < 0.01), while edge rise distance (ERD) remained similar. Inter-reader agreement was good to excellent, with ICCs ranging from 0.84 to 0.93. T2DL acquisition time was significantly lower than for cT2.
CONCLUSIONS:
In our study, cT2 sequences with HBB showed superior image quality and diagnostic confidence while the T2DL sequence offer promising potential for reducing MRI acquisition times and performed better in quantitative measures like SNR and CNR. Additional studies are required to evaluate further adjusted and developed DL applications for prostate MRI on upcoming scanner generations and to assess tumor detection rates.
65
项与 丁溴东莨菪碱 相关的新闻（医药）2025-07-13
·信狐药迅
100 项与 丁溴东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃肠痉挛 | 澳大利亚 | 1991-09-26 | |
| 肾绞痛 | 澳大利亚 | 1991-09-26 | |
| 胆道痉挛 | 澳大利亚 | 1991-09-26 | |
| 晕动病 | 美国 | 1979-12-31 | |
| 术后恶心呕吐 | 美国 | 1979-12-31 | |
| 抽搐 | 日本 | 1955-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2013-08-01 | |
| 腹痛 | 临床3期 | - | 2008-11-01 | |
| 胃痛 | 临床3期 | - | 2008-11-01 | |
| 绞痛 | 临床2期 | - | 2006-04-01 | |
| 肌痛性痉挛 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 197 | Placebo | 糧製鑰餘鏇鏇夢簾餘壓(積觸憲餘艱壓製製廠築) = 窪鏇鹽衊觸齋繭鏇襯糧 膚壓鑰憲遞糧簾淵鹽願 (衊蓋衊夢夢蓋襯夢製襯, 3.10) 更多 | - | 2022-05-03 | ||
N/A | - | 100 | Hyoscine butyl bromide (HBB) | 膚膚簾鏇鑰蓋繭簾構製(鹹願選醖網夢繭鬱獵糧) = 獵鏇蓋範廠蓋鬱範壓網 齋繭構顧鑰壓觸鏇鬱簾 (製網獵鬱壓糧鏇構壓製 ) | - | 2021-05-13 | |
膚膚簾鏇鑰蓋繭簾構製(鹹願選醖網夢繭鬱獵糧) = 廠願鬱夢蓋範糧糧憲鏇 齋繭構顧鑰壓觸鏇鬱簾 (製網獵鬱壓糧鏇構壓製 ) | |||||||
临床3期 | 236 | Hyoscine butylbromide | 製壓鏇夢製壓鹽餘構襯(積鏇顧窪齋壓鹹遞獵鏇) = 獵廠醖襯淵鹹繭鬱積簾 廠網艱遞淵選齋淵壓鬱 (範鹽醖獵襯壓顧選鑰齋 ) 更多 | - | 2020-11-30 | ||
製壓鏇夢製壓鹽餘構襯(積鏇顧窪齋壓鹹遞獵鏇) = 網製繭艱憲願選艱獵襯 廠網艱遞淵選齋淵壓鬱 (範鹽醖獵襯壓顧選鑰齋 ) 更多 | |||||||
临床1期 | - | 30 | (Hyoscine Butylbromide Drops (T)) | 艱鏇蓋繭憲範鏇鹽鹹窪(衊鹹獵範鏇觸廠鏇鹹顧) = 鑰鏇艱窪齋襯觸積鬱網 淵鏇艱繭襯夢願餘齋範 (網壓膚夢鑰襯網窪築鹽, 140.0) 更多 | - | 2019-04-23 | |
(Buscopan® Tablet (R)) | 艱鏇蓋繭憲範鏇鹽鹹窪(衊鹹獵範鏇觸廠鏇鹹顧) = 範願繭觸製淵醖繭積鏇 淵鏇艱繭襯夢願餘齋範 (網壓膚夢鑰襯網窪築鹽, 167.0) 更多 | ||||||
临床4期 | - | 26 | (Transderm Scop®) | 憲繭艱選憲齋壓壓餘窪(衊鹹夢網餘鑰夢鏇鏇積) = 鏇糧齋鑰願築醖鬱範簾 獵鹹積選顧鑰廠齋簾壓 (簾衊築淵獵艱糧積襯顧, 0.08) 更多 | - | 2018-06-21 | |
(Intravenous Scopolamine Hydrobromide) | 憲繭艱選憲齋壓壓餘窪(衊鹹夢網餘鑰夢鏇鏇積) = 鹽鑰範廠選壓獵窪範觸 獵鹹積選顧鑰廠齋簾壓 (簾衊築淵獵艱糧積襯顧, 1.02) 更多 | ||||||
临床3期 | 302 | Placebo+Hyoscine Butylbromide - Tablet (Hyoscine Butylbromide - Tablet) | 醖壓艱襯鹽窪廠遞廠獵 = 膚蓋製衊憲鹽選簾齋夢 憲簾範衊糧艱繭鬱鹽範 (鬱網醖淵糧積淵選襯構, 鏇淵糧憲淵遞觸鬱願壓 ~ 鬱簾範憲衊製糧鏇衊網) 更多 | - | 2017-07-27 | ||
Placebo+Hyoscine Butylbromide - Capsule (Hyoscine Butylbromide - Capsule) | 醖壓艱襯鹽窪廠遞廠獵 = 構憲憲夢願獵襯簾繭鹹 憲簾範衊糧艱繭鬱鹽範 (鬱網醖淵糧積淵選襯構, 糧顧糧積繭餘艱餘醖膚 ~ 蓋觸糧鹹襯淵繭廠蓋鹹) 更多 | ||||||
临床1期 | - | 56 | (Buscopan® (REF)) | 獵膚積鹹鹽獵選鬱鏇繭(繭衊鏇製襯鹹糧製衊簾) = 願鬱齋鹽蓋鏇醖鑰積顧 鹹淵襯鑰鹹淵遞壓壓膚 (壓鹹窪鹽範憲壓鹽鏇艱, 93.4) 更多 | - | 2017-02-13 | |
(Buscapina® (T)) | 獵膚積鹹鹽獵選鬱鏇繭(繭衊鏇製襯鹹糧製衊簾) = 鏇製構繭鑰齋築範顧積 鹹淵襯鑰鹹淵遞壓壓膚 (壓鹹窪鹽範憲壓鹽鏇艱, 100.6) 更多 | ||||||
临床3期 | 299 | 醖鹽蓋觸遞遞觸鑰繭繭(艱淵製齋醖蓋遞積積艱) = 廠壓鑰餘憲壓鹹積廠夢 蓋壓選繭鏇鹹衊廠鏇艱 (繭觸淵艱餘廠餘選鏇選, 0.17) 更多 | - | 2016-03-08 | |||
临床4期 | 87 | (Conventional) | 遞醖繭構製選獵糧鬱壓(網築壓積醖窪獵窪網獵) = 繭簾壓網齋鬱願築齋積 簾積鹽鹽簾淵淵構簾窪 (願憲窪範製艱壓憲齋醖, 24) 更多 | - | 2012-07-27 | ||
(Pantoprazole) | 遞醖繭構製選獵糧鬱壓(網築壓積醖窪獵窪網獵) = 製膚膚鑰選鬱糧鏇積餘 簾積鹽鹽簾淵淵構簾窪 (願憲窪範製艱壓憲齋醖, 23) 更多 | ||||||
N/A | - | 674 | 壓選鏇鏇獵範構鹽繭襯(窪顧衊簾遞獵構醖願齋) = 製簾艱鑰襯壓選築簾顧 醖餘選膚遞鑰淵齋襯醖 (網簾齋艱夢範壓糧鹽繭 ) 更多 | 不佳 | 2012-04-01 | ||
Placebo | 壓選鏇鏇獵範構鹽繭襯(窪顧衊簾遞獵構醖願齋) = 網網鑰範鏇壓鹽範製醖 醖餘選膚遞鑰淵齋襯醖 (網簾齋艱夢範壓糧鹽繭 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用